OBJECTIVES: Anecdotal evidence suggests that second-generation antipsychotic agents are increasingly used to treat sleep problems. This study sought to quantify the proportion of new prescriptions for second-generation antipsychotic agents started for sleep/sedation and the correlates of such use. DESIGN: A cross-sectional survey of provider decision making at the time second-generation antipsychotic agents were prescribed, documenting the reasons for the medication, patient demographics, psychiatric and medical diagnoses, patient health characteristics, and provider background. SETTING: A single Veterans Affairs Medical Center over a 20-month period. PARTICIPANTS: Prescribers of second-generation antipsychotic agents. INTERVENTIONS: N/A. RESULTS: Seven hundred seven (32.2%) of 2,613 surveys indicated sleep/sedation was at least one reason for using a second-generation anti-psychotic agent, whereas for 266 (12.1%) it was the only reason. Quetiapine was most frequently prescribed overall as well as for sleep/sedation (47.0% and 73.6% respectively). Second-generation antipsychotic agent use for sleep/sedation was unrelated to sociodemographic characteristics, least likely in patients with schizophrenia or bipolar disorder, and most likely as a newly started second-generation antipsychotic agent. CONCLUSION: Sleep/sedation is a common reason given for new prescriptions of second-generation antipsychotic agents. Quetiapine is most frequently used for this purpose. A greater understanding of why providers use second-generation antipsychotic agents rather than safer and less costly alternatives for sleep problems may advance the development of interventions to reduce adverse effects.
OBJECTIVES: Anecdotal evidence suggests that second-generation antipsychotic agents are increasingly used to treat sleep problems. This study sought to quantify the proportion of new prescriptions for second-generation antipsychotic agents started for sleep/sedation and the correlates of such use. DESIGN: A cross-sectional survey of provider decision making at the time second-generation antipsychotic agents were prescribed, documenting the reasons for the medication, patient demographics, psychiatric and medical diagnoses, patient health characteristics, and provider background. SETTING: A single Veterans Affairs Medical Center over a 20-month period. PARTICIPANTS: Prescribers of second-generation antipsychotic agents. INTERVENTIONS: N/A. RESULTS: Seven hundred seven (32.2%) of 2,613 surveys indicated sleep/sedation was at least one reason for using a second-generation anti-psychotic agent, whereas for 266 (12.1%) it was the only reason. Quetiapine was most frequently prescribed overall as well as for sleep/sedation (47.0% and 73.6% respectively). Second-generation antipsychotic agent use for sleep/sedation was unrelated to sociodemographic characteristics, least likely in patients with schizophrenia or bipolar disorder, and most likely as a newly started second-generation antipsychotic agent. CONCLUSION: Sleep/sedation is a common reason given for new prescriptions of second-generation antipsychotic agents. Quetiapine is most frequently used for this purpose. A greater understanding of why providers use second-generation antipsychotic agents rather than safer and less costly alternatives for sleep problems may advance the development of interventions to reduce adverse effects.
Authors: D B Allison; J L Mentore; M Heo; L P Chandler; J C Cappelleri; M C Infante; P J Weiden Journal: Am J Psychiatry Date: 1999-11 Impact factor: 18.112
Authors: Noah S Philip; Kerry Mello; Linda L Carpenter; Audrey R Tyrka; Lawrence H Price Journal: Ann Clin Psychiatry Date: 2008 Jan-Mar Impact factor: 1.567
Authors: Daniel M Hartung; Jennifer P Wisdom; David A Pollack; Ann M Hamer; Dean G Haxby; Luke Middleton; Bentson H McFarland Journal: J Clin Psychiatry Date: 2008-10 Impact factor: 4.384
Authors: Cenk Tek; Laura B Palmese; Andrew D Krystal; Vinod H Srihari; Pamela C DeGeorge; Erin L Reutenauer; Sinan Guloksuz Journal: Schizophr Res Date: 2014-10-29 Impact factor: 4.939
Authors: Christopher B Miller; Lisa Valenti; Christopher M Harrison; Delwyn J Bartlett; Nick Glozier; Nathan E Cross; Ronald R Grunstein; Helena C Britt; Nathaniel S Marshall Journal: J Clin Sleep Med Date: 2017-06-15 Impact factor: 4.062